source
- Syndax halts Niktimvo trial for idiopathic pulmonary fibrosis after mid-stage failureSyndax announced it will stop testing Niktimvo (axatilimab) in idiopathic pulmonary fibrosis after the Phase 2 MAXPIRe trial failed to meet its primary endpoint. The study enrolled 145 patients an…
- Pfizer strikes over $500M partnership with Enodia to develop Sec61-targeting small-molecule drugsPfizer's venture arm helped fund Enodia Therapeutics with a $25 million seed round earlier this year. The two companies have now announced a collaboration that could be worth more than $500 millio…